ES2162792T3 - Derivados de benzanilida como antagonistas de 5-ht1d. - Google Patents

Derivados de benzanilida como antagonistas de 5-ht1d.

Info

Publication number
ES2162792T3
ES2162792T3 ES92202806T ES92202806T ES2162792T3 ES 2162792 T3 ES2162792 T3 ES 2162792T3 ES 92202806 T ES92202806 T ES 92202806T ES 92202806 T ES92202806 T ES 92202806T ES 2162792 T3 ES2162792 T3 ES 2162792T3
Authority
ES
Spain
Prior art keywords
group
hydrogen
compounds
halogen atom
substitutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92202806T
Other languages
English (en)
Inventor
Alexander William Oxford
William Leonard Mitchell
John Bradshaw
John Watson Clitherow
Malcolm Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919119931A external-priority patent/GB9119931D0/en
Priority claimed from GB929205338A external-priority patent/GB9205338D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2162792T3 publication Critical patent/ES2162792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL INVENTO OFRECE COMPUESTOS DE LA FORMULA GENERAL (I): O UN SOLVATO O SAL FISIOLOGICAMENTE ACEPTABLE CONSIGUIENTE DONDE R1 REPRESENTA UN ATOMO DE HIDROGENO, UN ATOMO HALOGENO O UN GRUPO SELECCIONADO DE C1 TA UN GRUPO FENILO OPCIONALMENTE SUSTITUIDO POR UN GRUPO SELECCIONADO DE Y OPCIONALMENTE SUSTITUIDO ADEMAS POR UNO O DOS SUSTITUYENTES SELECCIONADOS DE ATOMOS HALOGENOS, C1 IDROXI, C1 6 ALQUILO; R3 REPRESENTA EL GRUPO R4 Y R5, QUE PUEDEN SER IGUALES O DIFERENTES, CADA UNO INDEPENDIENTEMENTE REPRESENTA UN ATOMO DE HIDROGENO O UN ATOMO HALOGENO, O UN GRUPO SELECCIONADO DE HIDROXI, C1 ESENTA UN ATOMO DE HIDROGENO O UN GRUPO SELECCIONADO DE NMR9R10 Y UN GRUPO C1 SUSTITUYENTES SELECCIONADOS DE C1 CILOXI Y ENTES, CADA UNO INDEPENDIENTEMENTE REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO C1 HIDROGENO O UN GRUPO SELECCIONADO DE C1ILO, BENZOILO Y LO O UN GRUPO FENILO: Z REPRESENTA UN ATOMO DE OXIGENO O UN GRUPO SELECCIONADO DE NR18 Y S(O)K; Y K REPRESENTA CERO, 1 O 2. LOS COMPUESTOS PUEDEN UTILIZARSEEN EL TRATAMIENTO O PROFILAXIS DE DEPRESION Y OTROS TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL.
ES92202806T 1991-09-18 1992-09-14 Derivados de benzanilida como antagonistas de 5-ht1d. Expired - Lifetime ES2162792T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919119931A GB9119931D0 (en) 1991-09-18 1991-09-18 Chemical compounds
GB929205338A GB9205338D0 (en) 1992-03-12 1992-03-12 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2162792T3 true ES2162792T3 (es) 2002-01-16

Family

ID=26299553

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92202806T Expired - Lifetime ES2162792T3 (es) 1991-09-18 1992-09-14 Derivados de benzanilida como antagonistas de 5-ht1d.

Country Status (26)

Country Link
US (2) US5340810A (es)
EP (1) EP0533268B1 (es)
JP (1) JP3295143B2 (es)
KR (1) KR930006011A (es)
CN (1) CN1071919A (es)
AP (1) AP303A (es)
AT (1) ATE204262T1 (es)
AU (1) AU656021B2 (es)
CA (1) CA2078505A1 (es)
CZ (1) CZ285492A3 (es)
DE (1) DE69232003T2 (es)
DK (1) DK0533268T3 (es)
ES (1) ES2162792T3 (es)
FI (1) FI924160A (es)
HU (1) HUT65608A (es)
IL (1) IL103198A (es)
IS (1) IS1618B (es)
MX (1) MX9205280A (es)
MY (1) MY130233A (es)
NO (1) NO923618L (es)
NZ (1) NZ244373A (es)
OA (1) OA10049A (es)
PL (1) PL295960A1 (es)
PT (1) PT533268E (es)
RU (1) RU2077535C1 (es)
TW (1) TW224097B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (es) * 1992-12-30 1995-02-11 Glaxo Group Ltd
WO1995004729A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
JPH09504004A (ja) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用アミドおよび尿素誘導体
EP0716656A1 (en) * 1993-09-03 1996-06-19 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
JP3328936B2 (ja) * 1993-09-03 2002-09-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
WO1995011243A1 (en) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
WO1995015954A1 (en) * 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9326008D0 (en) * 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
JPH09506885A (ja) * 1993-12-21 1997-07-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
EP0758330A1 (en) * 1994-05-06 1997-02-19 Smithkline Beecham Plc Biphenylcarboxamides useful as 5-ht1d antagonists
WO1995032967A1 (en) * 1994-05-28 1995-12-07 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
FR2722788B1 (fr) * 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5527920A (en) * 1994-11-18 1996-06-18 Singh; Inder P. Economical manufacturing process for 1,2,3-triazoles
CZ192397A3 (en) 1994-12-22 1997-09-17 Smithkline Beecham Plc Tetracyclic spiro-compounds, process of their preparation and use as 5ht1d receptors
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EP0861257A1 (en) * 1995-11-08 1998-09-02 Smithkline Beecham Plc Spiro piperidine derivatives as 5mt receptor antagonists
US5670526A (en) * 1995-12-21 1997-09-23 Otsuka Pharmaceutical Co., Ltd. 1,3,4-oxadiazoles
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
FR2744450A1 (fr) * 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9605945D0 (en) * 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
KR100305071B1 (ko) 1996-03-29 2001-12-12 디. 제이. 우드, 스피겔 알렌 제이 벤질-락탐유도체및/또는벤질리덴-락탐유도체,이들의제조방법및이들의세로토닌1에이및/또는세로토닌1디수용체의선택적인길항제및/또는작용제로서의용도
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761064B1 (fr) * 1997-03-20 1999-06-04 Pf Medicament Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
CN1260781A (zh) * 1997-04-18 2000-07-19 史密丝克莱恩比彻姆有限公司 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
EP1003738B1 (en) 1997-08-09 2003-11-19 SmithKline Beecham plc Bicyclic compounds as ligands for 5-ht1 receptors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SK492001A3 (en) * 1998-07-20 2001-08-06 Merck Patent Gmbh Biphenyl derivatives
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002044159A2 (en) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
NZ533865A (en) 2002-02-12 2006-02-24 Smithkline Beecham Corp Nicotinamide derivates useful as p38 inhibitors
ES2487816T3 (es) 2002-03-20 2014-08-25 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
AU2004212985B2 (en) * 2003-02-20 2010-10-14 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US20050215551A1 (en) * 2004-03-25 2005-09-29 Solvay Pharmaceuticals B.V. 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MX2007004215A (es) 2004-10-13 2007-12-12 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-metansulfonilfenil)-1-n- propilpiperidina.
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007077457A2 (en) * 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
EP2596000B1 (en) 2010-07-23 2016-04-20 The Board of Trustees of the University of Illionis Apparatus and methods for the automated synthesis of small molecules
CN103429235A (zh) * 2010-12-15 2013-12-04 赖鸿政 用于治疗癌症的化合物及其应用
CN103261185B (zh) 2010-12-17 2014-12-10 田边三菱制药株式会社 连续芳环化合物
CA2856749A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EP2862856B1 (en) * 2012-06-15 2018-08-01 Mitsubishi Tanabe Pharma Corporation Imidazole and triazole compounds as dgat-1 inhibitors
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023205475A1 (en) * 2022-04-21 2023-10-26 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192213A (en) * 1962-10-12 1965-06-29 Olin Mathieson Aminoalkyl anilides
DE1668723A1 (de) * 1966-09-16 1971-04-08 Toyo Jozo Kk Verfahren zum Herstellen von Verbindungen mit Saeureamid-Bindung
US4058523A (en) * 1974-10-14 1977-11-15 Chugai Seiyaku Kabushiki Kaisha Bis(benzamido)-benzene derivatives
AU499714B2 (en) * 1974-10-14 1979-05-03 Chugai Seiyaku Kabushiki Kaisha Bis(benzamido)-benzene derivatives & process for preparing thesame
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
DE3005287A1 (de) * 1980-02-13 1981-08-20 Basf Ag, 6700 Ludwigshafen Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
DE3100575A1 (de) * 1981-01-10 1982-09-02 Dr. Karl Thomae Gmbh, 7950 Biberach "neue benzoesaeuren, ihre herstellung und ihre verwendung als arzneimittel"
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3600288A1 (de) * 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4853398A (en) * 1987-04-13 1989-08-01 Eli Lilly And Company Leukotriene antagonists and use thereas
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
ZA89135B (en) * 1988-01-11 1989-10-25 Duphar Int Res Method of treating hematologic diseases and pharmaceutical composition to be used therefor
DE3810848A1 (de) * 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
ES2052890T3 (es) * 1988-10-10 1994-07-16 Akzo Nv Un metodo para la sintesis de compuestos aromaticos di- y trisubstituidos.

Also Published As

Publication number Publication date
IL103198A0 (en) 1993-02-21
OA10049A (en) 1996-10-14
MX9205280A (es) 1993-03-01
FI924160A0 (fi) 1992-09-17
IS3915A (is) 1993-03-19
AP9200427A0 (en) 1992-10-31
DE69232003T2 (de) 2002-04-25
CA2078505A1 (en) 1993-03-19
JPH06116251A (ja) 1994-04-26
PT533268E (pt) 2002-02-28
FI924160A (fi) 1993-03-19
AU2453092A (en) 1993-03-25
TW224097B (es) 1994-05-21
ATE204262T1 (de) 2001-09-15
CN1071919A (zh) 1993-05-12
KR930006011A (ko) 1993-04-20
DK0533268T3 (da) 2001-12-03
PL295960A1 (en) 1993-09-06
EP0533268A1 (en) 1993-03-24
HUT65608A (en) 1994-07-28
EP0533268B1 (en) 2001-08-16
AU656021B2 (en) 1995-01-19
MY130233A (en) 2007-06-29
JP3295143B2 (ja) 2002-06-24
RU2077535C1 (ru) 1997-04-20
US5510350A (en) 1996-04-23
IS1618B (is) 1996-10-18
US5340810A (en) 1994-08-23
DE69232003D1 (de) 2001-09-20
IL103198A (en) 1996-06-18
HU9202968D0 (en) 1992-12-28
NO923618D0 (no) 1992-09-17
CZ285492A3 (en) 1993-04-14
AP303A (en) 1994-01-28
NO923618L (no) 1993-03-19
NZ244373A (en) 1995-03-28

Similar Documents

Publication Publication Date Title
ES2162792T3 (es) Derivados de benzanilida como antagonistas de 5-ht1d.
FR2676443B1 (fr) Nouveaux derives de perhydroisoindole et leur preparation.
IL100384A0 (en) Serotonin antagonists,their preparation and pharmaceutical compositions containing them
ES2040276T3 (es) Derivados de la indolizina, procedimiento para su preparacion y composiciones que los contienen.
ES2123829T3 (es) Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.
DK0411668T3 (da) Central-cholecystokinin-antagonister til behandling af psykiatriske forstyrrelser
ES2058630T3 (es) Derivados de 2-(1-piperazinil)-4-fenilcicloalcanopiridinas, procedimientos de preparacion y composiciones farmaceuticas que los contienen.
DE60041710D1 (de) Polycycloalkylpurine als adenosinrezeptorantagonisten
ATE111910T1 (de) Lactamderivate.
FR2663934B1 (fr) Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
UY24482A1 (es) Quinoxalinadionas
EP0385722A3 (en) Tricyclic lactam derivatives and pharmaceutical compositions containing them
NO901082D0 (no) Fremgangsmaate for fremstilling av tetrahydrokinolin-derivater.
NO920945D0 (no) Nye 8-substituerte puriner som selektive adenosinreseptormidler
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DK1230241T3 (da) Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
ES2062165T3 (es) Derivado de piperidina, metodo para su preparacion, y una composicion farmaceutica que comprende el mismo.
DK0444853T3 (da) Hexahydrobenz(cd)indoler
IL65802A (en) 1-(3-fluoro-2-pyridinyl)piperazine and salts thereof,their preparation and pharmaceutical compositions containing them
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
EP0356098A3 (en) Lactam derivatives
ATE117980T1 (de) Serotonin-antagonisten.
HUP0400154A2 (hu) Heterokondenzált benzoxazepin- és benzoxatiazepin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 533268

Country of ref document: ES